Entering text into the input field will update the search result below

Achieve Life Sciences, Inc. (ACHV) Q3 2022 Earnings Call Transcript

Nov. 14, 2022 8:14 PM ETAchieve Life Sciences, Inc. (ACHV)
SA Transcripts profile picture
SA Transcripts

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET

Company Participants

Nicole Jones - Investor Relations-CG Capital

John Bencich - Chief Executive Officer

Jerry Wan - Principal Accounting Officer

Cindy Jacobs - President & Chief Medical Officer

Conference Call Participants

Thomas Flaten - Lake Street Capital

François Brisebois - Oppenheimer

Michael Higgins - Ladenburg Thalmann

John Vandermosten - Zacks

Jim Molloy - Alliance Global Partners


Good day, ladies and gentlemen, and welcome to Achieve Life Sciences Third Quarter 2022 Earnings Conference Call. All lines have been placed on a listen-only mode. And the floor will be open for questions and comments following the presentation. [Operator Instructions]

At this time, it is my pleasure to turn the floor over to your host Nicole Jones, CG Capital Investor Relations. Ma'am, the floor is yours.

Nicole Jones

Thank you, operator. On today's call from Achieve we have John Bencich Chief Executive Officer; and Jerry Wan Principal Accounting Officer. Achieve management will be available for Q&A after the prepared remarks.

I'd like to remind everyone that today's conference call contains forward-looking statements based on current expectations. These statements are only predictions and actual results may vary materially from those projected. Please refer to Achieve document available on our website and filed with the SEC concerning factors that could affect the company.

I'll now turn the call over to John.

John Bencich

Thank you, Nicole and thanks everyone for joining us today. It was yet again a busy and exciting quarter for Achieve. As we continue to advance cytisinicline through the clinic and closer to becoming the first new prescription treatment for nicotine dependence in nearly two decades.

In September, we announced completion of target enrollment in our confirmatory Phase III ORCA-3 trial for smoking cessation. And just last

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.